Analysts' Perspective: Eldorado Gold, Valeant Pharmaceuticals, CyberArk Software, Rolls-Royce Holdings
Brokerage firm Goldman Sachs upgraded Eldorado Gold Corp. (NYSE:EGO) shares from a Hold to a Buy rating
Eldorado Gold owns and operates mines around the world, primarily gold mines but also a silver-lead-zinc mine.
Analysts at RBC Capital Markets maintained a Sector Perform rating on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) stock but raised their price target from $31.00 to $36.00. Separately, brokerage firm Piper Jaffray reiterated an Underweight rating on shares of the company while increasing its price target from $19.00 to $22.00
Valeant Pharmaceuticals is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Equities researchers at DA Davidson reiterated a Neutral rating on CyberArk Software, Ltd. (Nasdaq:CYBR) shares while increasing their price target from $51.00 to $55.00. Separately, analysts at Deutsche Bank maintained a Buy rating on the company's stock but raised their price target from $50.00 to $60.00
CyberArk Software provides information technology (IT) security solutions that protect organizations from cyber-attacks.
Investment analysts at Morgan Stanley upgraded Rolls-Royce Holdings PLC (OTCMKTS:RYCEY) stock from an Underweight to an Equal-Weight rating
Rolls-Royce Holdings is a provider of an integrated power and propulsion solutions.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer